News : meeting, Molecular Targets, Press Releases, Conference

Panel of Melanoma Mutations Opens Door to New Treatment Possibilities

AACR News — Tue, 15 Nov 2011 21:30:57 GMT

Panel is a valuable tool for hypothesis generation and testing. BRAF is the most common melanoma mutation. Findings validate patient-derived tumor models. SAN FRANCISCO — Researchers have developed a new genetic screening tool that will aid in the...(read more)

Antifolates Show Promise Against NSCLC Subtype

AACR News — Mon, 14 Nov 2011 01:30:49 GMT

Aggressive lung cancers harboring KRAS mutations are sensitive to antifolates. Antifolates decrease KRAS gene expression. Large clinical trials needed to investigate antifolate effects in cancers with respect to driving mutations. SAN FRANCISCO —...(read more)

New Approaches May Prevent Certain Side Effects in BRAF Mutation-Positive Melanoma

AACR News — Sun, 13 Nov 2011 21:30:11 GMT

Recently discovered BRAF inhibitors may prevent drug-induced skin lesion side effects and lead to greater treatment durability. Mechanism of drug-induced skin lesions is explored in preclinical model. SAN FRANCISCO — Findings from preclinical studies...(read more)

Novel Monoclonal Antibody Offers Potential Treatment for Tumors Resistant to VEGF Therapy

AACR News — Sun, 13 Nov 2011 20:00:57 GMT

Shutting down the ALK-1 receptor inhibits the VEGF pathway. Response seen in patients who had used antiangiogenic therapy. VEGF therapies might work best in combination. SAN FRANCISCO — Despite the widespread use of current antiangiogenic cancer...(read more)

Researchers Develop More Effective Way to Discover and Test Potential Cancer Drugs

AACR News — Sun, 13 Nov 2011 20:00:56 GMT

Phenotypic platform better predicts cancer drug effectiveness from the lab to actual tumors. Platform reduces time and money spent on drugs that will not work or will be toxic. Platform removes researcher bias in choosing systems to target for drug discovery...(read more)

Combination Therapy Shows Potent Tumor Growth Inhibition in Preclinical Studies

AACR News — Sun, 13 Nov 2011 20:00:07 GMT

VEGF and Ang2 are critical factors required for tumor angiogenesis. Combined blockade of VEGF and Ang2 with investigational agents enhances antitumor activity in preclinical studies. Combination of REGN910 with aflibercept warrants further clinical investigation...(read more)

Signaling Pathway Linked to Inflammatory Breast Cancer May Drive Disease Metastasis

AACR News — Sun, 13 Nov 2011 16:00:28 GMT

Findings represent first evidence of ALK activity in inflammatory breast cancer. Data emphasize importance of proteins and enzymes to define molecular biology. Identification of ALK pathway activation could allow for more targeted treatment. SAN FRANCISCO...(read more)

HDAC Inhibitor May Overcome Resistance to Common Breast Cancer Drug

AACR News — Sun, 13 Nov 2011 16:00:09 GMT

HDAC inhibitor with tamoxifen treatment reduced tumor cell resistance in estrogen receptor-positive breast cancer. Critical pathway by which tumors become tamoxifen resistant identified. Early introduction of HDAC inhibitor with tamoxifen is key. SAN...(read more)

Embargo Policy for the AACR-NCI-EORTC Molecular Targets Meeting

AACR News — Wed, 12 Oct 2011 16:48:23 GMT

SAN FRANCISCO – The American Association for Cancer Research announces the following embargo policy for the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, to be held in San Francisco Nov. 12-16, 2011. The policy states...(read more)